Published online Nov 26, 2020. doi: 10.4252/wjsc.v12.i11.1295
Peer-review started: July 1, 2020
First decision: July 30, 2020
Revised: September 6, 2020
Accepted: September 27, 2020
Article in press: September 27, 2020
Published online: November 26, 2020
Processing time: 147 Days and 20.5 Hours
Breast cancer, like many other cancers, is believed to be driven by a population of cells that display stem cell properties. Recent studies suggest that cancer stem cells (CSCs) are essential for tumor progression, and tumor relapse is thought to be caused by the presence of these cells. CSC-targeted therapies have also been proposed to overcome therapeutic resistance in breast cancer after the traditional therapies. Additionally, the metabolic properties of cancer cells differ markedly from those of normal cells. The efficacy of metabolic targeted therapy has been shown to enhance anti-cancer treatment or overcome therapeutic resistance of breast cancer cells. Metabolic targeting of breast CSCs (BCSCs) may be a very effective strategy for anti-cancer treatment of breast cancer cells. Thus, in this review, we focus on discussing the studies involving metabolism and targeted therapy in BCSCs.
Core Tip: Breast cancer is thought to be driven by breast cancer stem cells (BCSCs). Recent studies suggest that BCSCs are essential for tumor progression and relapse, thus triggering therapeutic resistance in breast cancer after the traditional therapies. Moreover, the metabolic features of breast cancer cells are different from those of normal cells. BCSCs alter their metabolic profiles to fulfil bioenergetic and biosynthetic demands to maintain cancer cell survival. Here, we review the research regarding metabolism and targeted therapy in BCSCs.